|
|
|
|
|
Especially in times of crisis—like the current COVID-19 pandemic—there is no time or resource to waste on the issues that stem from contaminated or defective drug packaging. Large molecule drug formulations can be sensitive and easily impaired by stray particulates, excess silicone or packaging imperfections.
Components like plungers for prefilled syringes and stoppers and caps for vials come into direct contact with the drugs. While the onus is on biopharmaceutical manufacturers to ensure drugs reach patients in a sterile, secure condition up to and throughout point-of-use, there are ways to extend quality-centric standards for added reinforcement at the supplier level.
Datwyler, a global manufacturer of high-performing and system-critical primary packaging components for injectable drugs, takes great responsibility to help these companies mitigate the risk posed by contamination and defects in pharmaceutical packaging. The company pioneered the FirstLine™ manufacturing standard that better protects formulation integrity and ultimately patients, by applying a “Quality First” approach to manufacturing that combines cleanroom technology and automation.
Click here to learn how Datwyler helps drug manufacturers prioritize patient care with a "Quality First" approach and download our white paper detailing the FirstLine™ manufacturing standard.
|
|
|
|
|
|
|
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of BioPharm and Pharmaceutical Technology, MJH Life Sciences™ brands. You are on the mailing list as %%Member_Addr%%.
|
|
|
|
